Both BAFF‐R monoclonal antibody and BAFF‐R CAR T cells treatments have shown cytotoxic efficacy against various B‐cell malignancies, including acute lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and diffuse large B‐cell lymphoma.35, 47. This evidence concerns the gene TNFRSF13C and diffuse large B-cell lymphoma.